Alpha Stem Cell Clinics Trials

The Alpha Stem Cell Clinics Network is pursuing its goal to accelerate the development and delivery of stem cell treatments to patients through high quality clinical trials. 

Browse the list of ongoing trials at Alpha Stem Cell Clinic locations in the table below. You can sort trials based on different fields by clicking on the appropriate column header. Trials are automatically listed by status of trial enrollment and Alpha Clinic location.

Alpha Clinic Trials

Alpha Clinic	Alpha Clinic Contact	Trial Sponsor	Disease Indication	Clinical Trial Name	Status of Enrollment	Learn More
UCI	Julia Kimberly Fong juliakf@hs.uci.edu	Cartesian Therapeutics	MYASTHENIA GRAVIS (MG)	Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)	Recruiting	Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)
UC Davis	Jane McCluskey 916-703-9302 jmccluskey@hotmail.com	Capricor Therapeutics	COVID	A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Intravenous Delivery of CAP-1002 in Patients with Severe COVID-19	No longer active	A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Intravenous Delivery of CAP-1002 in P
UC Davis	Jane McCluskey 916-703-9302 jmccluskey@ucdavis.edu	Capricor Therapeutics	Duchenne Muscular Dystrophy	Open-Lael Extension of the HOPE-2 Duchenne Muscular Dystrophy Trial (HOPE-2-OLE)	Recruiting	Open-Lael Extension of the HOPE-2 Duchenne Muscular Dystrophy Trial (HOPE-2-OLE)
UC Davis	Jane McCluskey 916-703-9302 jmccluskey@ucdavis.edu	Capricor Therapeutics	Muscle - Duchenne Muscular Dystrophy	A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy (HOPE-2)	No longer active
UCLA	Maricela Gonzalez (310) 557-3729 mmgonzalez@mednet.ucla.edu	Calimmune	HIV/AIDS	Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection	No longer active
UCSD		Calibr	Relapsed/Refractory B-cell Lymphomas	Long term follow-up study for patients administered CLBR001 , a CAR-T cell	No longer active	Long term follow-up study for patients administered CLBR001 , a CAR-T cell
UCSD		Calibr	Relapsed/Refractory B-cell Lymphomas	CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies	No longer active	CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies
UC Davis	Jane McCluskey 916-703-9302 jmccluskey@ucdavis.edu	Cabaletta	Pemphigus Vulgaris	Phase 1, Open-label, Safety and Dosing Study of Autologous Desmoglein 3 Chimeric Autoantibody Receptor T Cells (DSG3-CAART) in Subjects with Active, Anti-DSG3, Mucosal-dominant Pemphigus Vulgaris	Recruiting	Phase 1, Open-label, Safety and Dosing Study of Autologous Desmoglein 3 Chimeric Autoantibody Receptor T Cells (DSG3-CAART) in S
UCI	UCI Stem Cell Clinic (949) 824-3990 stemcell@uci.edu	BrainStorm Cell Therapeutics	Amyotrophic Lateral Sclerosis (ALS)	A phase 3, randomized, double-blind, placebo-controlled multicenter study to evaluate efficacy and safety of repeated administrations of NurOwn® (autologous mesenchymal stem cells secreting neurotrophic factors) in participants with ALS	No longer active
UCI	Breana Chew 949-824-8116 chewbc@hs.uci.edu	Brain Neurotherapy Bio	Parkinson's	Open-Label Safety Study of Glial Cell Line-Derived Neurotrophic Factor Gene Transfer (AAV2- GDNF) in Parkinson’s Disease	Active, not recruiting
UCSF	Cyrus Bascon 510-428-3885 ext 5396 CBascon@mail.cho.org	bluebird bio	Sickle Cell Disease	A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in Severe Sickle Cell Disease	No longer active	NCT02140554
UCSF and UC Davis	Julie DeCaris 510-428-3885. ext.2739 Julie.decaris@ucsf.edu Jane McCluskey 916-703-9302 jmccluskey@ucdavis.edu	Bioverativ Therapeutics, Inc	Sickle Cell Disease	A Phase 1/2, Open-Label, Multicenter, Single-Arm Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients with Severe Sickle Cell Disease	No longer active
UC Davis	Jane McCluskey 916-703-9302 jmccluskey@ucdavis.edu	Autolus	Acute Lymphoblastic Leukaemia	An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia	Active, not recruiting	An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD1
City of Hope	Erminia Massarelli, MD 626-218-9200 emassarelli@coh.org	Atara Bio.	Cancer - Nasopharyngeal Carcinoma	Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)	No longer active
UC Davis	Jane McCluskey 916-703-9302 jmccluskey@ucdavis.edu	Atara Bio.	EBV-PTLD	Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study)	No longer active
UC Davis	Jane McCluskey 916-703-9302 jmccluskey@ucdavis.edu	Atara Bio	Hematologic Malignancies	An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects with Epstein-Barr Virus-associated Diseases	Recruiting	An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects with Epstei
UCSD	(844) 317-7836 alphastemcellclinic@ucsd.edu	Asterias Biotherapeutics	Spinal Cord Injury	Dose Escalation Study of AST-OPC1 in Spinal Cord Injury	No longer active
City of Hope	Rie Miyahira 626-256-4673 ext 80032 rmiyahira@coh.org	Angiocrine Bioscience	Cancer - Leukemia	A Phase 1B, Open Label, Multi-Center Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation	Recruiting
UC Davis	Jane McCluskey 916-703-9302 jmccluskey@ucdavis.edu	AlloVir	Kidney transplant	Phase 2 multicenter, randomized, double-blind, placebo-controlled, multiple dosing interval, 3-period study of the safety, tolerability and effectiveness of adoptively transferred Viralym-M multivirus-specific T cells in kidney transplant recipients with	No longer active	Phase 2 multicenter, randomized, double-blind, placebo-controlled, multiple dosing interval, 3-period study of the safety, toler
UCSF	Gabrielle Garcia Gabriel.Garcia@ucsf.edu	Allo Vir, Inc.	BK Viremia in Kidney Transplant Recipients	Phase 2 study in patients with BK Viremia in Kidney Transplant Recipients	No longer active	NCT04605484
UCI & UCSD & UC Davis	UCI Stem Cell Clinic 949-824-3990 stemcell@uci.edu Jane McCluskey 916-703-9302 jmccluskey@ucdavis.edu	Aivita Biomedical	Cancer - Brain	Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma	Active, not recruiting
UCSD		Aivita	Ovarian and Fallopian Tube Carcinoma	Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas	Active, not recruiting	Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcino
City of Hope	Hormoz Babaei Mirshkarlo 626-218-8074 hmirshkarlo@coh.org	Adaptimmune	Cancer - Myeloma	NY-ESO-1ᶜ²⁵⁹T Alone and in Combination With Pembrolizumab for Multiple Myeloma	Recruiting
City of Hope	Warren Chow, MD (626) 256-4673 x89200 wchow@coh.org	Adaptimmune	Cancer - Sarcoma	A Pilot Study of Genetically Engineered NY-ESO-1 Specific (c259) T Cells in HLA-A2+ Patients With Synovial Sarcoma	Active, not recruiting
City of Hope	Mihaela Cristea, MD (626) 256-4673 x89200 mcristea@coh.org	Adaptimmune	Cancer - Ovarian	A Phase I/IIa, Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Patients With Recurrent or Treatment Refractory Ovarian Cancer.	Recruiting
City of Hope	Karen Reckamp, MD (626) 256-4673 x89200 kreckamp@coh.org	Adaptimmune	Cancer - Lung	Screening Protocol for Tumor Antigen Expression and HLA Sub-Type in NSCLC	Recruiting
City of Hope	Karen Reckamp, MD (626) 256-4673 x89200 kreckamp@coh.org	Adaptimmune	Cancer - Lung	A Phase I/II Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)	Recruiting
City of Hope	Karen Reckamp, MD (626) 256-4673 x89200 kreckamp@coh.org	Adaptimmune	Cancer - Lung	A Phase I/ II Dose Escalation Open Label Clinical Trial Evaluating the Safety and Efficacy of MAGE A10ᶜ⁷⁹⁶T in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)	Active, not recruiting
UCSF & UC Davis	Hanjing Zhou 415-502-7434 hanging.zhou@ucsf.edu		COVID-19/ARDS	Mesenchymal Stromal Cells for ARDS (COVID positive and COVID negative)	No longer active

Clinical trials conducted at CIRM Alpha Stem Cell Clinics must comply with applicable federal and state laws and medical and ethical standards governing the conduct of human clinical trials. If you or a family member is interested in participating in a clinical trial, please visit clinicaltrials.gov to find a trial near you.

Find Out More:
About Alpha Stem Cell Clinics
Alpha Clinics News